Literature DB >> 16652422

Cepharanthin, a biscoclaurine alkaloid, prevents destruction of acinar tissues in murine Sjögren's syndrome.

Masayuki Azuma1, Yuki Ashida, Tetsuya Tamatani, Katsumi Motegi, Natsumi Takamaru, Naozumi Ishimaru, Yoshio Hayashi, Mitsunobu Sato.   

Abstract

OBJECTIVE: Our previous study suggested that suppression by cepharanthin of tumor necrosis factor-a (TNF-a)-induced matrix metalloproteinase-9 (MMP-9) could prevent destruction of the acinar structure in the salivary glands of patients with Sjögren's syndrome (SS). In this study, we observed that in vivo administration of cepharanthin prevented severe damage to acinar tissues in the murine model of human SS.
METHODS: Cepharanthin was intraperitoneally administered to thymectomized female NFS/sld mice. Inflammatory lesions in the salivary and lacrimal glands were then examined histologically. Expression of phosphorylated IkB-a, MMP-9, and type IV collagen was analyzed immunohistochemically. The apoptotic cell death of acinar cells was determined.
RESULTS: Although extensive mononuclear cell infiltration and destruction of acinar tissue in salivary and lacrimal glands were observed in control mice, significant improvement of these lesions was evident in mice treated with cepharanthin. Immunohistochemical analysis revealed that p65, phosphorylated IkB-a, and MMP-9 were more strongly stained in the acinar cells of control mice than in cepharanthin-treated mice. Although no staining for type IV collagen was observed in the acinar tissues of control mice, continuity of staining for type IV collagen was observed in acinar tissues of cepharanthin-treated mice. Destruction of acinar tissues was attributed to the induction of apoptosis, suggesting that cepharanthin inhibits apoptosis by suppressing phosphorylation of IkB-a, followed by prevention of MMP-9 activation.
CONCLUSION: Our findings suggest that cepharanthin may be a promising agent for use in preventing destruction of acinar tissues in murine SS.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16652422

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  6 in total

1.  Cepharanthine Inhibits IFN-γ-Induced CXCL10 by Suppressing the JAK2/STAT1 Signal Pathway in Human Salivary Gland Ductal Cells.

Authors:  Keiko Aota; Tomoko Yamanoi; Koichi Kani; Masayuki Azuma
Journal:  Inflammation       Date:  2018-02       Impact factor: 4.092

Review 2.  Mouse Models of Primary Sjogren's Syndrome.

Authors:  Young-Seok Park; Adrienne E Gauna; Seunghee Cha
Journal:  Curr Pharm Des       Date:  2015       Impact factor: 3.116

3.  Pathological Analysis of Ocular Lesions in a Murine Model of Sjögren's Syndrome.

Authors:  Aya Ushio; Rieko Arakaki; Hiroshi Eguchi; Fumika Hotta; Akiko Yamada; Yasusei Kudo; Naozumi Ishimaru
Journal:  Int J Mol Sci       Date:  2017-06-06       Impact factor: 5.923

4.  Determination of cepharanthine in rat plasma by LC-MS/MS and its application to a pharmacokinetic study.

Authors:  Yingbin Deng; Weijun Wu; Sunzhi Ye; Wei Wang; Zhiyi Wang
Journal:  Pharm Biol       Date:  2017-12       Impact factor: 3.503

Review 5.  Cepharanthine: An update of its mode of action, pharmacological properties and medical applications.

Authors:  Christian Bailly
Journal:  Phytomedicine       Date:  2019-05-10       Impact factor: 5.340

Review 6.  Recent Advances in Mouse Models of Sjögren's Syndrome.

Authors:  Yunzhen Gao; Yan Chen; Zhongjian Zhang; Xinhua Yu; Junfeng Zheng
Journal:  Front Immunol       Date:  2020-06-30       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.